2seventy bio, Inc. (NASDAQ:TSVT) Receives Consensus Recommendation of “Moderate Buy” from Analysts

2seventy bio, Inc. (NASDAQ:TSVTGet Free Report) has received a consensus recommendation of “Moderate Buy” from the ten ratings firms that are presently covering the company, Marketbeat reports. Five analysts have rated the stock with a hold rating, four have assigned a buy rating and one has given a strong buy rating to the company. The average 1-year price objective among brokers that have issued a report on the stock in the last year is $12.86.

TSVT has been the subject of several research reports. Canaccord Genuity Group cut their price target on 2seventy bio from $12.00 to $11.00 and set a “buy” rating for the company in a research note on Thursday, May 9th. Citigroup upped their price target on shares of 2seventy bio from $9.00 to $12.00 and gave the company a “buy” rating in a research note on Monday, April 8th. Wedbush reiterated a “neutral” rating and issued a $5.00 price objective on shares of 2seventy bio in a research note on Monday, March 18th. Leerink Partnrs upgraded 2seventy bio from a “market perform” rating to an “outperform” rating in a research report on Wednesday, January 31st. Finally, TD Cowen reiterated a “market perform” rating on shares of 2seventy bio in a research report on Wednesday, January 31st.

Read Our Latest Analysis on TSVT

Insider Transactions at 2seventy bio

In related news, Director Casdin Capital, Llc bought 330,000 shares of the firm’s stock in a transaction that occurred on Monday, March 25th. The shares were bought at an average cost of $5.07 per share, with a total value of $1,673,100.00. Following the acquisition, the director now owns 1,960,000 shares in the company, valued at $9,937,200. The purchase was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Company insiders own 2.60% of the company’s stock.

Hedge Funds Weigh In On 2seventy bio

Several hedge funds have recently modified their holdings of TSVT. Tower Research Capital LLC TRC increased its stake in 2seventy bio by 15.2% during the fourth quarter. Tower Research Capital LLC TRC now owns 14,629 shares of the company’s stock worth $62,000 after acquiring an additional 1,925 shares during the last quarter. ELCO Management Co. LLC purchased a new stake in 2seventy bio during the 3rd quarter valued at $67,000. Acadian Asset Management LLC bought a new stake in 2seventy bio in the third quarter worth $89,000. Deutsche Bank AG boosted its stake in 2seventy bio by 15.7% during the third quarter. Deutsche Bank AG now owns 26,134 shares of the company’s stock worth $102,000 after buying an additional 3,537 shares during the period. Finally, SG Americas Securities LLC boosted its stake in 2seventy bio by 20.9% during the fourth quarter. SG Americas Securities LLC now owns 27,315 shares of the company’s stock worth $117,000 after buying an additional 4,715 shares during the period. Hedge funds and other institutional investors own 93.90% of the company’s stock.

2seventy bio Trading Down 3.3 %

Shares of NASDAQ TSVT opened at $4.40 on Friday. The firm’s 50-day moving average price is $4.81 and its 200-day moving average price is $4.19. The firm has a market capitalization of $226.16 million, a P/E ratio of -1.01 and a beta of 1.87. 2seventy bio has a 1-year low of $1.53 and a 1-year high of $12.69.

2seventy bio (NASDAQ:TSVTGet Free Report) last released its quarterly earnings results on Tuesday, March 5th. The company reported ($1.11) EPS for the quarter, beating analysts’ consensus estimates of ($1.22) by $0.11. The business had revenue of $10.68 million during the quarter, compared to analyst estimates of $13.91 million. 2seventy bio had a negative return on equity of 67.59% and a negative net margin of 313.51%. During the same period in the prior year, the firm posted ($0.60) EPS. Equities research analysts forecast that 2seventy bio will post -0.93 EPS for the current year.

About 2seventy bio

(Get Free Report

2seventy bio, Inc, a cell and gene therapy company, focuses on the research, development, and commercialization of treatments for cancer in the United States. The company's products pipeline includes Abecma, a chimeric antigen receptor T-cell product candidates for the treatment of multiple myeloma.

Featured Articles

Analyst Recommendations for 2seventy bio (NASDAQ:TSVT)

Receive News & Ratings for 2seventy bio Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for 2seventy bio and related companies with MarketBeat.com's FREE daily email newsletter.